MBTPS1 and COVID-19: Furthermore, glucocorticoids, widely used in the treatment of COVID‐19 with contradictory effects (Ledford, 2020), target S1P signaling, by inhibiting S1P‐induced cytokine secretion (Che et al, 2014).